Encephalopathy - Pipeline Review, H1 2018

Encephalopathy - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H1 2018, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalopathy - Companies Involved in Therapeutics Development
Celgene Corp
Chiesi Farmaceutici SpA
GW Pharmaceuticals Plc
JS Genetics Inc
Knopp Biosciences LLC
Marinus Pharmaceuticals Inc
Mithra Pharmaceuticals SA
Pairnomix LLC
ProThera Biologics Inc
SciFluor Life Sciences LLC
Takeda Pharmaceutical Co Ltd
Zynerba Pharmaceuticals Inc
Encephalopathy - Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Kv7.2 for Central Nervous System Disorders and Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block KCNQ2 for Epileptic Encephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block SCN8A for Epileptic Encephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-935 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRP-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalopathy - Dormant Projects
Encephalopathy - Product Development Milestones
Featured News & Press Releases
Apr 10, 2018: Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
Jan 03, 2018: Zynerba Pharmaceuticals Provides Update on cannabidiol
Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy
Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Encephalopathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Encephalopathy - Pipeline by Celgene Corp, H1 2018
Encephalopathy - Pipeline by Chiesi Farmaceutici SpA, H1 2018
Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H1 2018
Encephalopathy - Pipeline by JS Genetics Inc, H1 2018
Encephalopathy - Pipeline by Knopp Biosciences LLC, H1 2018
Encephalopathy - Pipeline by Marinus Pharmaceuticals Inc, H1 2018
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H1 2018
Encephalopathy - Pipeline by Pairnomix LLC, H1 2018
Encephalopathy - Pipeline by ProThera Biologics Inc, H1 2018
Encephalopathy - Pipeline by SciFluor Life Sciences LLC, H1 2018
Encephalopathy - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Encephalopathy - Pipeline by Zynerba Pharmaceuticals Inc, H1 2018
Encephalopathy - Dormant Projects, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Encephalopathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018

Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018, provides an overview of the

USD 2000 View Report

Hepatic Encephalopathy - Pipeline Review, H2 2018

Hepatic Encephalopathy - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides an overview of the Hepatic Encephalopathy

USD 2000 View Report

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

USD 3500 View Report

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018Phosphatidylinositol 4,5

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available